Gynecologic and Obstetric Investigation
Original Paper
Total Lactate Dehydrogenase and Its Isozymes in Serum from Patients with Primary Carcinoma of the OvaryKikuchi Y.a · Hisano A.a · Kuki E.b · Hirata J.a · Nagata I.aaDepartment of Obstetrics and Gynecology, National Defense Medical College, Saitama, and bDepartment of Obstetrics and Gynecology, Aida Hospital, Fukushima, Japan
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: July 09, 1990
Accepted: November 12, 1990
Published online: March 02, 2010
Issue release date: 1991
Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 0
ISSN: 0378-7346 (Print)
eISSN: 1423-002X (Online)
For additional information: https://www.karger.com/GOI
Abstract
Serum lactate dehydrogenase (LDH), its isozymes and Α-hydroxybutyrate dehydrogenase (HBD) were examined in 57 patients with primary carcinoma of the ovary and compared to those in 220 patients with benign ovarian tumor. Serum LDH, LDH-4, LDH-5 and HBD in patients with ovarian carcinoma were significantly higher than those in patients with benign ovarian tumor. Except for the percent fraction of LDH-5, LDH activity, LDH-4 activity, percent fraction of LDH-4, LDH-5 activity and HBD activity in patients with ovarian carcinoma correlated significantly with stage of disease. The positive result of ovarian carcinoma was highest at LDH-4 activity (43.6%), followed by LDH activity (42.1 %), HBD activity (34.6%), LDH-5 activity (32.7%), percent fractions of LDH-4 and LDH-5 (20.0%). On the other hand, the false-positive rate in patients with benign ovarian tumor was highest at LDH activity (12.7%), followed by HBD activity (10.0%), LDH-5 activity (8.6%), percent fraction of LDH-5 (8.2%), LDH-4 activity (6.8%) and percent fraction LDH-4 (3.6%). The detection rate for early ovarian carcinoma (stages I and II) was elevated from 4.5 % by HBD activity alone to 50.0% by a combination assay of LDH, LDH-4, LDH-5 and HBD, while that for advanced ovarian carcinoma (stages III and IV) was elevated from 50.0% by HBD alone to 79.4% by the combination assay. LDH and LDH-4 activities in the serum of patients with endometrioid carcinoma were significantly higher than those in the serum of patients with serous cystadenocarcinoma, while percent fraction of LDH-4 in the serum of patients with endometrioid carcinoma was significantly higher than that in the serum of patients with mucinous cystadenocarcinoma, suggesting a correlation with the histological type of the tumor.
© 1991 S. Karger AG, Basel
Related Articles:
Article / Publication Details
Received: July 09, 1990
Accepted: November 12, 1990
Published online: March 02, 2010
Issue release date: 1991
Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 0
ISSN: 0378-7346 (Print)
eISSN: 1423-002X (Online)
For additional information: https://www.karger.com/GOI
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
